Vaccine type |
Age,
Number of doses |
Route and dose |
Minimum dosing interval (months) |
Notes |
Diphtheria Tetanus
Pertussis (DTP, dTp) |
<4 years
4 or 5 doses DTPa
|
IM
0.5 ml |
1,1*,6** |
3 doses for primary series then **4th dose at 18 months of age or 6 months after primary course. If 4 doses of DTP given before age 18 months, give a 5th dose at 4 years, reflecting the NIP which includes dose 4 at 18 months and dose 5 at 4 years. If the 4th dose is given after the child is 3.5 years the 5th dose is not required, and in this case the next dose is the early adolescent booster dose. A hexavalent vaccine is available in all jurisdictions, (combining DTPa with IPV/Hib/HepB). *If using the hexavalent vaccine combined with hepatitis B, the dosing interval changes (2 months between doses 2 and 3 and 4 months between dose 1 and 3). |
4-9 years
4 doses DTPa |
IM
0.5 ml |
1,1*,6** |
3 doses for primary series then **4th dose 6 months after primary course. Hexavalent vaccine as above. |
10 years and older
3 doses (dTpa) |
IM
0.5 ml |
1,1 |
Up to 3 doses of dTpa may now be used (previously dTpa, dT, dT), then 10-year and 20-year booster dTpa. dTpa is now available combined with IPV (dTpa-IPV).
dTpa is also recommended for pregnant women between 20-32 weeks gestation in every pregnancy (can be given any time up to delivery); partners of women who are at least 28 weeks gestation if no booster for 10 years, and parents of children <6 months if no booster for 10 years. |
Measles
Mumps
Rubella (MMR)
(LAV) |
<10 years
2 doses
|
IM or SC*
0.5 ml |
1 |
2nd dose due at 3.5–4 years if
<3.5 years at first dose.
MMR (*given IM) is now available combined with Varicella Vaccine (VV) as MMR-V (*given SC) – although MMR-V is not recommended as the first dose of MMR containing vaccine in children
<4 years, due to increased risk of fever/febrile convulsions in this setting.
Recent changes (April 2019) have lowered the recommended age at which infants can receive MMR in special circumstances - from 9 months to 6 months. Infants 6 months and older can receive MMR as post-exposure prophylaxis, or during outbreaks (or for travel to endemic areas). |
10 years and older (born 1966 or later)
2 doses |
IM or SC*
0.5 ml |
1 |
Note: MMR now given as part of Departure Health Check for Offshore Humanitarian arrivals aged 9 months – 54 years, consider timing if administering TST for tuberculosis (TB) screening or live viral vaccines.
MMR-V (*given SC) can be given as the first dose in children 4 years and older (followed by MMR alone), but is not recommended in those aged 14 years and older. |
Inactivated
Poliomyelitis Vaccine (IPV) |
<4 years
4 doses*
4 years and older
3 doses |
Varies** 0.5 ml |
1,1, varies*
1,1 |
*4th dose required if aged
<4 years for primary course. Different combination vaccines available, combined with DTPa/dTpa/HiB/Hep B. Hexavalent vaccine dosing as above. Also available as dTpa-IPV.
**IPV in combination vaccines given IM, IPV alone given SC. Note: OPV and IPV are considered interchangeable (OPV may have been given prior to travel to Australia from
certain countries). |
Hepatitis B |
<11 years
3 doses
|
IM
0.5 ml |
1,2** |
Combination vaccines are available, *dosing intervals complex, minimal dosing intervals: 1 month between dose 1 and 2; 2 months between doses 2 and 3; and 4 months between dose 1 and 3. |
11-15 years
2 doses (adult formulation) |
IM
1 ml |
4 |
Alternate regimen is 3 doses paediatric formulation (0.5 ml) as above. |
16 years and older
3 doses* |
IM
varies** |
1,2** |
*Age 16–19 years 3 doses paediatric formulation (0.5 ml), 20 years and older 3 doses adult formulation (1 ml). Dosing intervals as above. |
Meningococcal ACWY |
Any*
1 or 2 doses** |
IM
0.5 ml |
(2) |
*Normally given at age 12 months, disease has bimodal peaks in incidence of
<5 years and 15–24 years, MenC catch-up previously funded to 19 years (born>1987). Consider providing MenACWY if previous meningococcal vaccination was provided as MenC.
**Nimenrix = 1 dose, Menveo/Menactra = 2 doses, 8 weeks apart. |
15-19 years (year 10 or equivalent) 1 dose |
IM 0.5 ml |
– |
Also provided for year 10 students (and available in Victoria for those aged 15–19 years, State-based program).
Additional
doses of meningococcal ACWY vaccine recommended in asplenia. |
Haemophilus
influenzae
type b (Hib) |
2-17 months
1-3 doses then booster*
18-59 months
1 dose |
IM
0.5 ml |
1 or 2*
varies* 2 |
Required in children
<5 years of age. Not required 5 years and older, unless special circumstances, including
asplenia but may be given as part of combination vaccines. Children
<10 years generally receive multiple doses of Hib through the use of combination vaccines (e.g. hexavalent DTPa/IPV/HiB/HepB).
Refer to Immunisation Handbook for catch-up schedule in younger children – <7 months – 3 doses then booster at 18 months, 7–11 months 2 doses then booster at 18 months, 12–17 months 1 dose then booster at 18 months or 2 months after last dose (whichever is later). If a child has received PRP-OMP Hib vaccine for the first 2 doses, they do not require a 3rd dose but should still have a booster at 18 months. |
Pneumococcal
conjugate (13vPCV) |
<12 months
3 doses
12–59 months
1 dose |
IM 0.5 ml |
1,1
–
|
Now given at 2,4 and 12 months of age in NIP, with an extra dose at 6m for children with medical risk factors.
Required in all children
<5 years of age, and 5 years and older if medical risk factors. If providing catch-up for children who have medical risk factors:
<12 months – 4 doses required, and 12-59 months – 2 doses required. Dosing interval is 1 month for <12 months age or 2 months for 12 months of age and older.
People with medical risk factors require extra doses of 13vPCV and 23vPPV
(minimum 8 weeks apart) see Immunisation Handbook. |
Pneumococcal polysaccharide (23vPSV) |
65 years |
IM 0.5 ml |
– |
Age 65 years and older.
People with medical risk factors as above. See Immunisation Handbook. |
Varicella (VV)
(LAV) |
18 months –
13 years
1 dose
14 years and older*
2 doses |
SC
0.5 ml |
–
1 |
All children
<14 years should have at least one dose of VV (and preferably two doses of VV), usually given as either VV or MMR-V at 18 months. Prior varicella infection is not a contraindication. If varicella containing vaccine is given
<12 months of age, the dose should be repeated at 18 months. MMR-V is not recommended as the first dose of MMR containing vaccine in children <4 years, due to increased risk of fever/febrile convulsions, and is not recommended in those aged 14 years and older.
*VV is recommended in non-immune adolescents/adults 14 years and older (no clinical history and negative serology). People 14 years and older with a reliable history of varicella should be considered immune; check serology if no clinical history of varicella infection. |
Herpes zoster (LAV) |
70-79 years
1 dose |
SC
0.5 ml |
– |
Recommended at age 70 years, 5-year catch-up program available for those age 71–79 years (starting 2018). Exclude previous dosing and contraindications, and check
decision aid. |
Human Papilloma Virus (HPV) |
9-25 years - suggest 12-25 years to match NIP. 1 dose* |
IM
0.5 ml |
|
*Changed to single dose regimen Feb 2023 for immune competent people aged 9-25 years (reducing lower age and raising upper age for catch-up (from 19 years), however included at 12-13 years in NIP. Also recommended in all MSM (any age - consider past/future exposure, only funded to 25y), not recommended adults 26 years and older otherwise. Recommended for immunocompromised (suggest 9 years and older) - 3-dose schedule, 0,2,6 months (also noting licensing below). See Immunisation Handbook.
From 2018, 9-valent HPV given to all year 7 students (or age equivalent 12-13 years). 9-valent HPV funded 9-25 years inclusive as of Feb 2023. HPV vaccines not recommended during pregnancy, can be given during breastfeeding. Licensed for females age 9–45 years and males 9–26 years. Note licensed to 26 years, recommended to 25 years - discrepancy correct as of Feb 2023. |
Influenza (seasonal and annual) |
<9 years
1 or 2 doses*
9 years and older 1 dose
|
IM (dose varies) |
1
– |
Now recommended annually for all people 6 months and older, including pregnant women. In Victoria, funded for children
<5 years (from 2018), pregnant women, adults 65 years and older, and age 5 years and older with medical risk factors.
Dose and formulation vary with age and formulation – 0.5 ml age 6 months and older (Fluarix Tetra, Vaxigrip Tetra, FluQuadri), 0.5 ml 3 years and older (previous and also Influvac Tetra), 0.5 ml 5 years and older (previous and also Afluria Quad). Different formulations funded for adults 65 years and older (Fluad Quad 0.5 ml). *If aged
<9 years at the time of first administration – 2 doses minimum 1 month apart. Check Immunisation Handbook and
MVEC information . |
Covid |
6 months - 4 years - 2 doses* 5-11 years - 2 doses* + consider booster as recommended
12-15 years - 2 doses* + booster as recommended 16 years and older - 2 doses* + boosters as recommended |
IM (dose varies) |
Recommended 2m, minimum varies with type 3rd primary also recommended 2m if required Boosters 3m |
Children 6m-4 years with severe immunocompromise*, disability, complex/multiple health conditions -recommended interval 8-weeks. (Moderna paediatric 6m-5y, 25mcg dose - blue/purple, 2-dose primary course). *3 doses if severe immunocompromise - interval also 8 weeks. Children 5-11 years - 2 doses, recommended interval 8-weeks. Pfizer (registered age 5-11 years) = 1/3 adult dose (orange vial - 10mcg), minimum interval 3-weeks. Moderna (registered age 6-11 years, 50mcg, 1/2 adult dose), minimum interval 4 weeks. *Severely immunocompromised eligible for 3rd primary dose - interval 2-months after 2nd dose. No boosters. Children 12-15 years - 2 doses, recommended interval 8-weeks. Pfizer 30mcg dose, minimum interval 3-weeks, Moderna 100mcg dose, minimum interval 4-weeks. *Severely immunocompromised eligible for 3rd primary dose - interval 2-months after 2nd dose. Booster - only if severe immunocompromise, disability, complex/multiple conditions increasing risk severe covid-19. Age 16 years and older - 2 doses Pfizer interval 8-weeks, 30mcg dose, minimum 3-weeks, Moderna interval 8-weeks, 100mcg dose, minimum 4-weeks. *Severely immunocompromised eligible for 3rd primary dose - interval 2-months after 2nd dose). Novovax can be used age 18 years and older, interval 3-weeks, can extend to 8-weeks. AstraZeneca is available for age 60 years and older, and adults 18-59 years based on personal preference, interval 12-weeks, minimum 4-weeks. Boosters - mRNA vaccines preferred, given 3-months after primary course. 'Winter boosters' i.e. 2nd booster - available 30y+, recommended for age 50 years and older, and age 16y+ if resident aged care/disability facilities, complex/multiple conditions increasing risk severe illness, or severely immunocompromised, interval - 3-months after initial booster Therefore standard = 2 dose primary + boosters, immunocompromised = 3 dose primary + boosters. Overseas dosing and completion guide. Feb 2023, ATAGI guidelines for 2023 booster (regardless of prior doses, if 6-months after last covid vaccine or confirmed covid infection and aim for vaccine before June 2023) - recommended for all adults 65 years and older and adults 18-64 years with medical comorbidities or disability, consider all adults 18-64 years, children 5-17 years with medical co-morbidities or disability. Bivalent mRNA vaccines preferred (although all formulations acceptable) - Pfizer original/omicron BA.4/5 or original/omicron BA.1, or Moderna original/omicron BA.1. |
Rotavirus
(LAV) |
<6 months,
2 doses*
|
Oral 1.5 ml |
1 |
Not usually given
as catch-up due to strict age restrictions. Rotarix (1.5 ml): 2 doses at 2 and 4 months of age, 1st dose must be given
<15 weeks, 2nd dose must be given <25 weeks. |
Bacillus Calmette
Guerin (BCG)
(LAV) |
<16 years*,
1 dose
|
ID,
varies** |
– |
Recommended in:1,2
Children
<5 years in households with immigrants/unscreened visitors from high prevalence countries.
Children
<5 years travelling to high prevalence countries (i.e.>40 cases per 100,000 population per year) for >3 months (also consider cumulative travel).
Neonates with family history of leprosy.
*Consider in:
Exposure to active pulmonary TB where preventive therapy not possible/after completion preventive therapy.
Travel to high prevalence area >6 weeks if aged
<5 years, >3 months aged >5 years.[2]
Only give if no record/scar, no immunosuppression, no evidence TB infection (requires TST if previous travel, usually no TST if age
<2 years and no travel) and no other contraindications. **Dose is 0.05ml age <12 months, 0.1ml 12 months and older. Only available through RCH and Monash currently. |